Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

Company Overview - Unicycive Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for kidney diseases [2] - The company's lead investigational treatment is oxylanthanum carbonate, a phosphate binding agent under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis [2] - Unicycive's second investigational treatment, UNI-494, targets conditions related to acute kidney injury and has received orphan drug designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [2] Recent Developments - The company announced a change in the timing of its 2025 Annual Meeting of Stockholders, which will now be held at 7:00 a.m. Pacific Daylight Time on June 9, 2025 [1] - The location of the meeting remains unchanged at 4300 El Camino Real, Suite 210, Los Altos, CA 94022 [1] - Stockholders of record as of April 30, 2025, can find additional participation details on the company's dedicated webpage [1]